Skip to main content
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2005 Aug;76(8):1099–1102. doi: 10.1136/jnnp.2004.052415

The features of myasthenia gravis with autoantibodies to MuSK

D Lavrnic 1, M Losen 1, A Vujic 1, M De Baets 1, L Hajdukovic 1, V Stojanovic 1, R Trikic 1, P Djukic 1, S Apostolski 1
PMCID: PMC1739764  PMID: 16024887

Abstract

Objectives: To determine if myasthenia gravis (MG) with antibodies to MuSK is a distinct subgroup of seronegative MG.

Methods: We assayed antibodies to muscle specific tyrosine kinase (MuSK) in 55 MG patients who had no antibodies to acetylcholine receptors and looked for the specific phenotype, comparing clinical features of anti-MuSK positive and anti-MuSK negative MG patients.

Results: MG with anti-MuSK antibodies was characterised by a striking prevalence of female patients (15 women, two men). Age at onset ranged from 22 to 52 years, with 70.6% of patients presenting at <40 years of age. The majority of patients (82.4%) had prevalent involvement of facial and bulbar muscles. One third of them did not respond well to anticholinesterase drugs. Steroid immunosuppression was effective in eight patients (44.4%). Nine patients underwent thymectomy; six of these had no thymus pathology, while three had a hyperplastic thymus. At the end of the observation period, six (35.3%) patients were in remission, five (29.4%) improved, four (23.6%) did not change, and two (11.7%) had died.

Conclusions: MG patients with antibodies to MuSK have characteristic clinical features that are different from features of the remaining seronegative MG patients. This emphasises the predictive value of anti-MuSK antibody analysis in seronegative MG patients.

Full Text

The Full Text of this article is available as a PDF (63.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Besinger U. A., Toyka K. V., Hömberg M., Heininger K., Hohlfeld R., Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology. 1983 Oct;33(10):1316–1321. doi: 10.1212/wnl.33.10.1316. [DOI] [PubMed] [Google Scholar]
  2. Burges J., Vincent A., Molenaar P. C., Newsom-Davis J., Peers C., Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve. 1994 Dec;17(12):1393–1400. doi: 10.1002/mus.880171208. [DOI] [PubMed] [Google Scholar]
  3. Evoli Amelia, Tonali Pietro A., Padua Luca, Monaco Mauro Lo, Scuderi Flavia, Batocchi Anna P., Marino Mariapaola, Bartoccioni Emanuela. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003 Jun 23;126(Pt 10):2304–2311. doi: 10.1093/brain/awg223. [DOI] [PubMed] [Google Scholar]
  4. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001 Mar;7(3):365–368. doi: 10.1038/85520. [DOI] [PubMed] [Google Scholar]
  5. Lindstrom J. M. Acetylcholine receptors and myasthenia. Muscle Nerve. 2000 Apr;23(4):453–477. doi: 10.1002/(sici)1097-4598(200004)23:4<453::aid-mus3>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  6. McConville John, Farrugia Maria Elena, Beeson David, Kishore Uday, Metcalfe Richard, Newsom-Davis John, Vincent Angela. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004 Apr;55(4):580–584. doi: 10.1002/ana.20061. [DOI] [PubMed] [Google Scholar]
  7. Ohta K., Shigemoto K., Kubo S., Maruyama N., Abe Y., Ueda N., Ohta M. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology. 2004 Jun 8;62(11):2132–2133. doi: 10.1212/01.wnl.0000129274.12702.92. [DOI] [PubMed] [Google Scholar]
  8. Sanders D. B., El-Salem K., Massey J. M., McConville J., Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003 Jun 24;60(12):1978–1980. doi: 10.1212/01.wnl.0000065882.63904.53. [DOI] [PubMed] [Google Scholar]
  9. Scuderi Flavia, Marino Mariapaola, Colonna Lucrezia, Mannella Francesca, Evoli Amelia, Provenzano Carlo, Bartoccioni Emanuela. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest. 2002 Sep;82(9):1139–1146. doi: 10.1097/01.lab.0000028144.48023.9b. [DOI] [PubMed] [Google Scholar]
  10. Selcen Duygu, Fukuda Taku, Shen Xin-Ming, Engel Andrew G. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology. 2004 Jun 8;62(11):1945–1950. doi: 10.1212/01.wnl.0000128048.23930.1d. [DOI] [PubMed] [Google Scholar]
  11. Vincent Angela, Bowen John, Newsom-Davis John, McConville John. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol. 2003 Feb;2(2):99–106. doi: 10.1016/s1474-4422(03)00306-5. [DOI] [PubMed] [Google Scholar]
  12. Yeh Jiann-Horng, Chen Wei-Hung, Chiu Hou-Chang, Vincent Angela. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology. 2004 Jun 8;62(11):2131–2132. doi: 10.1212/01.wnl.0000128042.28877.c3. [DOI] [PubMed] [Google Scholar]
  13. Zhou Lan, McConville John, Chaudhry Vinay, Adams Robert N., Skolasky Richard L., Vincent Angela, Drachman Daniel B. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve. 2004 Jul;30(1):55–60. doi: 10.1002/mus.20069. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES